High-dose fenretinide in oral leukoplakia (Q34164825)

31 July 2017

High-dose fenretinide in oral leukoplakia (English)

1 reference

Vassiliki Papadimitrakopoulou

31 July 2017

oral mucosa leukoplakia

1 reference

10

Reuben Lotan

0 references

11

object named as

Vassiliki A Papadimitrakopoulou

1 reference

31 July 2017

3

Scott M Lippman

1 reference

31 July 2017

William N William

1

1 reference

31 July 2017

J Jack Lee

2

1 reference

31 July 2017

Jack W Martin

4

1 reference

31 July 2017

Nitin Chakravarti

5

1 reference

31 July 2017

Hai T Tran

6

1 reference

31 July 2017

Anita L Sabichi

7

1 reference

31 July 2017

Edward S Kim

8

1 reference

31 July 2017

Lei Feng

9

1 reference

31 July 2017

1 January 2009

1 reference

Cancer Prevention Research

31 July 2017

1 reference

31 July 2017

2

1 reference

31 July 2017

1

1 reference

31 July 2017

22-26

1 reference

Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer

31 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Pharmacokinetics of oral fenretinide in neuroblastoma patients: indications for optimal dose and dosing schedule also with respect to the active metabolite 4-oxo-fenretinide

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

The convergent development of molecular-targeted drugs for cancer treatment and prevention

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Identification of retinamides that are more potent than N-(4-hydroxyphenyl)retinamide in inhibiting growth and inducing apoptosis of human head and neck and lung cancer cells

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Effects of novel phenylretinamides on cell growth and apoptosis in bladder cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

N-(4-hydroxyphenyl)retinamide (4-HPR)-mediated biological actions involve retinoid receptor-independent pathways in human breast carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

13-cis-retinoic acid in the treatment of oral leukoplakia

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

A phase I-II preoperative biomarker trial of fenretinide in ascitic ovarian cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709).

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

A phase I clinical and pharmacokinetic study of fenretinide combined with paclitaxel and cisplatin for refractory solid tumors

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Randomized trial of fenretinide (4-HPR) to prevent recurrences, new localizations and carcinomas in patients operated on for oral leukoplakia: long-term results.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

Comparison of low-dose isotretinoin with beta carotene to prevent oral carcinogenesis.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4161148

N-(4-hydroxyphenyl)retinamide induces apoptosis of malignant hemopoietic cell lines including those unresponsive to retinoic acid

28 October 2018

1 reference

12 December 2020

Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation

1 reference

12 December 2020

Fenretinide activity in retinoid-resistant oral leukoplakia

1 reference

12 December 2020

N-(4-hydroxyphenyl)retinamide: a Potent Inducer of Apoptosis in Human Neuroblastoma Cells

1 reference

12 December 2020

Low-dose isotretinoin versus beta-carotene to prevent oral carcinogenesis: long-term follow-up

1 reference

12 December 2020

Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells

1 reference

12 December 2020

Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines

1 reference

12 December 2020

Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide

1 reference

12 December 2020

Green tea regulates cell cycle progression in oral leukoplakia.

0 references

Identifiers

DOI

10.1158/1940-6207.CAPR-08-0100

1 reference

31 July 2017

1 reference

31 July 2017

1 reference